3.1 0.6 (24%) | 11-01 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 4.42 | 1-year : | 5.17 |
Resists | First : | 3.78 | Second : | 4.42 |
Pivot price | 2.5 | |||
Supports | First : | 2.8 | Second : | 2.2 |
MAs | MA(5) : | 2.63 | MA(20) : | 2.48 |
MA(100) : | 2.6 | MA(250) : | 0 | |
MACD | MACD : | 0 | Signal : | -0.1 |
%K %D | K(14,3) : | 47.8 | D(3) : | 49.4 |
RSI | RSI(14): 70.3 | |||
52-week | High : | 3.78 | Low : | 2.2 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ EPRX ] has closed It is unclear right now based on current values. 63.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 3.79 - 3.81 | 3.81 - 3.82 |
Low: | 2.47 - 2.48 | 2.48 - 2.5 |
Close: | 3.08 - 3.1 | 3.1 - 3.12 |
Thu, 31 Oct 2024
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million - StockTitan
Fri, 02 Aug 2024
Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility - Canada NewsWire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 36 (M) |
Shares Float | 30 (M) |
Held by Insiders | 6.9 (%) |
Held by Institutions | 12.8 (%) |
Shares Short | 128 (K) |
Shares Short P.Month | 128 (K) |
EPS | -0.94 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0.41 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -98.7 % |
Return on Equity (ttm) | -314.5 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -0.9 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -26 (M) |
Levered Free Cash Flow | -15 (M) |
PE Ratio | -3.34 |
PEG Ratio | 0 |
Price to Book value | 7.38 |
Price to Sales | 0 |
Price to Cash Flow | -4.3 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |